MichaelEphraimWechslerMD
Pulmonology • Denver, COCritical Care Medicine, Pleural Disease
Director of Asthma - Dept of Medicine, National Jewish Health
Dr. Wechsler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1400 Jackson St
# National
Denver, CO 80206Phone+1 303-388-4461Fax+1 303-270-2206
Education & Training
Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 2000
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1993 - 1996
McGill University Faculty of MedicineClass of 1993
Certifications & Licensure
CO State Medical License 2012 - 2025
MA State Medical License 1995 - 2018
FL State Medical License 2013 - 2015- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- American Association of Physicians AAP, 2022
- Elected Member The American Society for Clinical Investigation, 2012
Clinical Trials
- Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Start of enrollment: 2007 Sep 01
- Characterization of Placebo Responses in Stable Asthma Start of enrollment: 2005 Jan 01
Publications & Presentations
PubMed
- 276 citationsEosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.Matthieu Groh, Christian Pagnoux, Chiara Baldini, Elisabeth H. Bel, Paolo Bottero
European Journal of Internal Medicine. 2015-09-01 - 510 citationsMepolizumab or Placebo for Eosinophilic Granulomatosis with PolyangiitisMichael E. Wechsler, Praveen Akuthota, David Jayne, Paneez Khoury, Amy D. Klion
The New England Journal of Medicine. 2017-05-17 - 75 citationsBenralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.Vamsi P. Guntur, Laurie A. Manka, Joshua L. Denson, Ryan M. Dunn, Yeshai T. Dollin
The Journal of Allergy and Clinical Immunology. in Practice. 2021-03-01
Journal Articles
- Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory FeaturesZachary M Dong, Michael E Wechsler, Praveen Akuthota, Peter A Merkel, Ulrich Specks, Benjamin Raby, Frederic Clayton, The American Journal of Pathology
- Baseline Patient Factor Impact on the Clinical Efficacy of Benralizumab for Severe AsthmaJames G Zangrilli, Michael E Wechsler, The European Respiratory Journal
- Care Pathways for the Selection of a Biologic in Severe AsthmaMichael E Wechsler, Wanda Phipatanakul, Nicola A Hanania, The European Respiratory Journal
Press Mentions
FDA Approves Benralizumab for Eosinophilic Granulomatosis with PolyangiitisSeptember 19th, 2024- Benralizumab Now FDA Approved to Treat EGPA VasculitisSeptember 19th, 2024
- FDA OKs New Option for Rare Immune-Mediated VasculitisSeptember 18th, 2024
- Join now to see all
Grant Support
- Anti- IL5 Therapy For Churg-Strauss Syndrome: A Double Blind Randomized, Placebo-National Institute Of Allergy And Infectious Diseases2010
- The Reliability Of The Placebo Effect In AsthmaNational Center For Complementary &Alternative Medicine2006–2007
- Polymorphisms Of Neural NOS And The Asthma PhenotypeNational Heart, Lung, And Blood Institute2001–2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
